Evocutis announces 2013 interim results

Published: 3-Apr-2013
Finance

Revenue reaches £226,000


Evocutis plc, the UK dermatology company, has announced its unaudited interim results for the six months ended 31 January, 2013.

The company reported a revenue of £226,000, up from £344,000 in H1 2012, while the cash balance totalled £1,030,000 at 31 January 2013. Adjusted operating loss totalled £476,000, while basic loss per share equalled 0.28p per share.

Operation highlights in the reporting period include the launch of LabSkin for direct sale in September 2012, and laboratory studies of LabSkin, which demonstrated its value as a living model system for studies of transdermal drug delivery, complementing the use of excised, non-living human or pig skin systems.

  • Companies:
  • Evocutis
See more

You may also like

Skin Care

Venn Life Sciences acquires trading assets of Evocutis

Read more
Including intellectual property rights to Labskin and anti-acne compound SYN1113

Trending Articles

  1. Former investor accuses Revolution Beauty of ‘deceit’ and seeks £45.2 million claim Chrysalis Investments is taking legal action against the fast beauty retailer, accusing it of ‘negligent misstatement and/or misrepresentation’
  2. PZ Cussons to sell St. Tropez in bid to return to growth The owner of Charles Worthington and Sanctuary Spa has struggled with declining sales with its Africa business hit by devaluation of the Nigerian naira
  3. THG revenue growth boosted by beauty's 'standout performance' The increased revenues reported in Q1 builds on THG’s return to growth in the final quarter of 2023
  4. Nivea helps push Beiersdorf sales to €4.9 billion in H1 Sun protection was pinpointed as a strong performance segment for the German giant's Nivea, Eucerin and Aquaphor brands
  5. The Body Shop administrators investigate claim of missing millions FRP Advisory is allegedly exploring the claim that millions of pounds were taken out of the company before it fell into administration

Upcoming event

China Beauty Expo

22-24 May | Shanghai, China See all

You may also like

Skin Care

Venn Life Sciences acquires trading assets of Evocutis

Including intellectual property rights to Labskin and anti-acne compound SYN1113
Finance

PZ Cussons to sell St. Tropez in bid to return to growth

The owner of Charles Worthington and Sanctuary Spa has struggled with declining sales with its Africa business hit by devaluation of the Nigerian naira
Finance

Former investor accuses Revolution Beauty of ‘deceit’ and seeks £45.2 million claim

Chrysalis Investments is taking legal action against the fast beauty retailer, accusing it of ‘negligent misstatement and/or misrepresentation’
Finance

THG revenue growth boosted by beauty's 'standout performance'

The increased revenues reported in Q1 builds on THG’s return to growth in the final quarter of 2023
Finance

The Body Shop's downfall triggered by failing to secure credit

The beauty company’s owner Aurelius Group failed to secure new funding, according to reports in The Telegraph
Finance

Puig sets IPO target for close to €14 billion

The Spanish beauty giant plans to sell Class B shares at €22 to €24.50 each, which would value the group between €12.7bn and €13.9bn
Finance

L’Oréal’s sales soar thanks to dermatological beauty​​ and mass make-up

The French beauty giant reported revenue of €11.24bn for the quarter, driven by increasing consumer demand for dermatological beauty and mass make-up
Subscribe now